Physicochemical Properties
| Molecular Formula | C22H31N5O5 |
| Molecular Weight | 445.51204 |
| Exact Mass | 445.232 |
| CAS # | 119670-30-3 |
| Related CAS # | Z-L(D-Val)G-CHN2 |
| PubChem CID | 73715817 |
| Appearance | Off-white to yellow solid powder |
| LogP | 3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 13 |
| Heavy Atom Count | 32 |
| Complexity | 697 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | N#[N+]/C=C(/CN[C@H](C(NC([C@@H](NC(OCC1C=CC=CC=1)=O)CC(C)C)=O)=O)C(C)C)\[O-] |
| InChi Key | KRMMQWXJLDORCJ-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C22H31N5O5/c1-14(2)10-18(26-22(31)32-13-16-8-6-5-7-9-16)20(29)27-19(15(3)4)21(30)24-11-17(28)12-25-23/h5-9,12,14-15,18-19H,10-11,13H2,1-4H3,(H,24,30)(H,26,31)(H,27,29) |
| Chemical Name | benzyl N-[1-[[1-[(3-diazo-2-oxopropyl)amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | EC50: 190 nM (SAR-COV-2)[3] |
| ln Vitro | Z-LVG-CHN2 (0-10 μM; 16 hours pretreatment) exhibits an EC50 value of 0.19 μM[1] and, in Vero E6 cells intended to capture multicycle replication, inhibits antiviral activity in a measurable dose-dependent manner. |
| Cell Assay |
Cell Viability Assay[3] Cell Types: Vero E6 cells Tested Concentrations: 0.001 μM, 0.003 μM, 0.1 μM, 0.3 μM, 1 μM, 2.5 μM Incubation Duration: Pre-treated for 16 h and then cultured for 24 hrs (hours) Experimental Results: Inhibited SARS-COV-2 virus replication in a dose-dependent manner. |
| References |
[1]. Inhibition of growth of human TE2 and C-33A cells by the cell-permeant calpain inhibitor benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone. Exp Cell Res. 1994 Nov;215(1):164-71. [2]. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J Virol. [3]. A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. bioRxiv. 2020 Apr 17;2020.04.16.044016. |
Solubility Data
| Solubility (In Vitro) | DMSO : 100 mg/mL (224.46 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.61 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.61 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (5.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2446 mL | 11.2231 mL | 22.4462 mL | |
| 5 mM | 0.4489 mL | 2.2446 mL | 4.4892 mL | |
| 10 mM | 0.2245 mL | 1.1223 mL | 2.2446 mL |